Nimotuzumab Not Clinically Efficacious in Glioblastoma

Share this content:

the Cancer Therapy Advisor take:

Glioblastoma (GBM) is a type of highly malignant brain tumor with poor prognosis. Epidermal growth factor receptors (EGF-R) have been linked to the oncogenesis of GBM, in which the EGF-RvIII variant is most commonly seen.

Agents targeting EGF-R, such as gefitnib and erlotnib, and monoclonal antibodies like cetuximab, have not demonstrated convincing efficacy for the treatment of GBM, however, antibody mediated therapy and vaccinations are being explored.

Nimotuzumab, a monoclonal antibody that has a greater specificity for EGF-R overexpressing cells compared to cetuximab, has shown promising efficacy for high grade glioma. Investigators conducted a randomized, open label trial to evaluate the efficacy of nimotuzumab in patients with newly diagnosed glioblastoma.

There were 149 patients in the study, stratified as with or without residual tumor, and were randomly assigned to receive either intravenous nimotuzumab added to standard radiotherapy or just standard radiotherapy.

Results showed that the 12-month PFS was seen in 25.6% of patients in the nimotuzumab group, and 20.3% in the control group. Of the patients with residual tumor (n=81), the median PFS was 5.6 months in the nimotuzumab group versus 4.0 months in the control group (HR 0.87; 95%CI, 0.55-1.37), and patients without residual tumor (n=61) 10.6 versus 9.9 months (HR, 1.01; 95%CI, 0.57-1.77).

The median OS in patients with residual tumor was 19.5 months in the nimotuzumab group versus 16.7 months in the control group (HR, 0.90; 95% CI, 0.52-1.57; P=0.7061), and patients without residual tumor 23.3 versus 21.0 months (HR, 0.77; 95% CI, 0.41-1.44; P=0.4068).

A cohort study was conducted on MGMT non-methylated patients with residual tumor and showed a PFS of 6.2 versus 4.0 months (HR, 0.77; 95% CI, 0.35-1.67; P=0.4997), and OS of 19.0 versus 13.8 months (HR, 0.66; 95% CI, 0.27-1.64; P=0.3648).

The authors concluded that EGF-R amplification does not correlate with clinical efficacy of nimotuzumab, and thus alternative explanations should be hypothesized for the treatment of GBM. The results of this study provided important information to plan for future trials. 

Grade IV: Glioblastoma multiforme (GBM)
Nimotuzumab has shown promising efficacy for high grade glioma.
A randomised, open label phase III trial was conducted to evaluate efficacy of nimotuzumab, a monoclonal antibody against epidermal growth factor receptor (EGF-R) added to standard therapy for newly diagnosed glioblastoma. This study, albeit negative, contains hypothesis generating signals supporting evaluation of correlative, efficacy-predicting tumour parameters for nimotuzumab in the treatment of glioblastoma.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs